EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Belzutifan in Individuals with von Hippel-Lindau Retinal Hemangioblastomas: Institutional Experience and Review of the Literature

Farzad Jamshidi, Lola Lozano, Budd Tucker, Jean Andorf, Elliott Sohn, Edwin Stone, Andrew Groves, Yousef Zakharia, H Culver Boldt, Elaine Binkley

Ocular Oncology and Pathology · 2024 · 10 (3) · 154-161

DOI: 10.1159/000539434 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Ocular Oncology and Pathology, online erschienen am 24.05.2024. Verfasst von Farzad Jamshidi und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Ophthalmology and Visual Sciences, University of Iowa, Iowa City, IA, USA. Die Arbeit wurde bisher 15-mal zitiert (Crossref) und nennt 18 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

The systemic HIF-2 alpha inhibitor, belzutifan, has been approved for use in patients with von Hippel-Lindau disease (VHL)-associated renal cell carcinoma, central nervous system (CNS) hemangioblastomas, and pancreatic neuroendocrine tumors. This drug has also shown promise in controlling VHL retinal hemangioblastomas (RHs), but little work has been published on the use of the drug in this setting.

Methods

We conducted a retrospective review of patients with VHL-associated RHs followed by the retina service at our institution who were treated with systemic belzutifan. Patient age, gender, genotype, presence of systemic tumors, indication for the drug, initial dose, adjusted dose, side effects, and tumor response were recorded. We also conducted a literature search for all manuscripts describing the effect of belzutifan on VHL-associated ocular tumors.

Results

We identified 12 eyes of 7 patients with VHL-associated ocular tumors who were treated with belzutifan at our institution. Of these, 5 eyes of 3 patients had progressing ocular tumors when belzutifan was started. Of the 7 total patients, 2 were treated for renal cell carcinoma, 2 for CNS hemangioblastomas, 2 for RHs, and one for pancreatic neuroendocrine tumors. Initial dose was 120 mg PO daily in 6 patients and 80 mg PO daily in 1 patient. The dose was reduced in all but 1 patient due to side effects. The ocular tumors were controlled in all patients with an average follow-up of 13 months (range 4–24 months). Literature review identified 7 manuscripts that described belzutifan-mediated control of ocular tumors in patients with VHL-associated RHs in 21 patients.

Conclusion

The drug belzutifan shows great promise for controlling RHs and preventing vision loss in patients with VHL. Further work needs to address the optimal dose, role of the drug as a neoadjuvant therapy, and long-term efficacy and tolerability of the drug in a larger cohort of patients with ocular tumors.

Schlagwörter

Stichwörter der Autor:innen

BelzutifanRetinal hemangioblastomavon Hippel-Lindau

Autor:innen und Institutionen

  • Department of Ophthalmology and Visual Sciences, University of Iowa, Iowa City, IA, USA.
  • Institute for Vision Research, University of Iowa, Iowa City, IA, USA.
  • Department of Pediatrics, University of Iowa, Iowa City, IA, USA.
  • Department of Internal Medicine, University of Iowa, Iowa City, IA, USA.

Zitieren

APA

Jamshidi, F., Lozano, L., Tucker, B., Andorf, J., Sohn, E., Stone, E., Groves, A., Zakharia, Y., Boldt, H. C., & Binkley, E. (2024). Belzutifan in Individuals with von Hippel-Lindau Retinal Hemangioblastomas: Institutional Experience and Review of the Literature. Ocular Oncology and Pathology, 10(3), 154-161. https://doi.org/10.1159/000539434

Vancouver

Jamshidi F, Lozano L, Tucker B, Andorf J, Sohn E, Stone E, et al. Belzutifan in Individuals with von Hippel-Lindau Retinal Hemangioblastomas: Institutional Experience and Review of the Literature. Ocular Oncology and Pathology. 2024;10(3):154-161. doi:10.1159/000539434

BibTeX
@article{Jamshidi2024,
  author = {Jamshidi, Farzad and Lozano, Lola and Tucker, Budd and Andorf, Jean and Sohn, Elliott and Stone, Edwin and Groves, Andrew and Zakharia, Yousef and Boldt, H Culver and Binkley, Elaine},
  title = {Belzutifan in Individuals with von Hippel-Lindau Retinal Hemangioblastomas: Institutional Experience and Review of the Literature},
  journal = {Ocular Oncology and Pathology},
  year = {2024},
  volume = {10},
  number = {3},
  pages = {154--161},
  doi = {10.1159/000539434}
}
Kostenlos starten →